文献速递细菌感染、耐药与抗菌药物医院感染防控

在多重耐药革兰阴性菌高流行地区COVID-19大流行期间实施的以碳青霉烯类为重点的抗菌药物管理项目

A carbapenem-focused antimicrobial stewardship programme implemented during the COVID-19 pandemic in a setting of high endemicity for multidrug-resistant Gram-negative bacteria.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

在希腊一家三级医院开展准实验前后对照研究,比较12个月干预期与12个月对照期。以碳青霉烯类为重点的抗菌药物管理项目使碳青霉烯类使用比例从4.1%降至2.3%,使用量下降4.9 DDD/100患者日,哌拉西林/他唑巴坦使用增加2.1 DDD/100患者日,30天死亡率与全因住院死亡率无变化,住院时间延长,30天内感染相关再入院风险降低。

要点

  • 碳青霉烯类使用比例从4.1%(842/20629)降至2.3%(426/18245)(-1.8%;P<0.001)。
  • 碳青霉烯类使用量下降4.9 DDD/100患者日(95%CI -7.3至-2.6;P=0.007)。
  • 干预后接受ASP干预与院内死亡每日风险降低相关(csHR 0.49;95%CI 0.30-0.80)。

核心结论

  • 在高抗菌药物耐药率地区实施并维持以碳青霉烯类为重点的抗菌药物管理项目是可行、有效且安全的,即使在COVID-19大流行期间。

研究设计与样本

  • 准实验前后对照研究,比较12个月干预前期与实施以碳青霉烯类为重点的抗菌药物管理项目的12个月干预期,共纳入1268例患者。

主要发现

  • 接受碳青霉烯类的住院患者比例从4.1%(842/20629)降至2.3%(426/18245)(-1.8%;P<0.001)。
  • 碳青霉烯类使用量下降4.9 DDD/100患者日(95%CI -7.3至-2.6;P=0.007),哌拉西林/他唑巴坦使用量增加2.1 DDD/100患者日(95%CI 1.0-3.3;P=0.010)。
  • 碳青霉烯类治疗启动后30天死亡率与全因住院死亡率在ASP实施后无变化。
  • 住院时间延长(中位数17.0天 vs 19.0天;P<0.001)。
  • 出院后30天内感染相关再入院风险降低(24.6% vs 16.8%;P=0.007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Greece is among the countries characterized by high rates of antimicrobial resistance and high consumption of antibiotics, including carbapenems. OBJECTIVES: To measure the impact of a carbapenem-focused antimicrobial stewardship programme (ASP) on the antibiotic consumption and patient outcomes in a Greek tertiary hospital during the COVID-19 pandemic. METHODS: A quasi-experimental, before-after study, comparing a 12 month pre-intervention period with a 12 month intervention period in which a carbapenem-focused ASP was implemented. RESULTS: A total of 1268 patients were enrolled. The proportion of admitted patients who received carbapenems decreased from 4.1% (842 of 20 629) to 2.3% (426 of 18 245) (-1.8%; P < 0.001). A decrease of -4.9 DDD/100 patient-days (PD) (95% CI -7.3 to -2.6; P = 0.007) in carbapenem use and an increase in the use of piperacillin/tazobactam [+2.1 DDD/100 PD (95% CI 1.0-3.3; P = 0.010)] were observed. Thirty-day mortality following initiation of carbapenem treatment and all-cause in-hospital mortality remained unaltered after ASP implementation. In contrast, length of hospital stay increased (median 17.0 versus 19.0 days; P < 0.001), while the risk of infection-related readmission within 30 days of hospital discharge decreased (24.6% versus 16.8%; P = 0.007). In the post-implementation period, acceptance of the ASP intervention was associated with lower daily hazard of in-hospital death [cause-specific HR (csHR) 0.49; 95% CI 0.30-0.80], lower odds of 30 day mortality (OR 0.36; 95% CI 0.18-0.70) and higher rate of treatment success (csHR 2.45; 95% CI 1.59-3.77). CONCLUSIONS: Implementing and maintaining a carbapenem-focused ASP is feasible, effective and safe in settings with high rates of antimicrobial resistance, even during the COVID-19 pandemic.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Spernovasilis N, Kritsotakis EI, Mathioudaki A, et al. A carbapenem-focused antimicrobial stewardship programme implemented during the COVID-19 pandemic in a setting of high endemicity for multidrug-resistant Gram-negative bacteria. J Antimicrob Chemother. 2023. PMID: 36790896. doi:10.1093/jac/dkad035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。